{
    "clinical_study": {
        "@rank": "55514", 
        "arm_group": [
            {
                "arm_group_label": "Ivacaftor (VX-770)", 
                "arm_group_type": "Experimental", 
                "description": "twice a day administration of Ivacaftor: 150mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "matching placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is a randomized, double-blind, placebo-controlled, multiple-dose, pilot  study of\n      orally-administered ivacaftor in subjects with chronic obstructive pulmonary disease.\n      Subjects will be administered the study drug ivacaftor 150 mg (or placebo) twice daily\n      (BID)."
        }, 
        "brief_title": "TOPIC Trial for COPD", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or Female age 40-65\n\n          -  A Clinical diagnosis of COPD as defined by GOLD\n\n          -  At Least a 10 pack year smoking history\n\n          -  Exhibit symptoms of chronic bronchitis defined by MRC\n\n          -  FEV1% predicted \u2265 35% and \u226470% Post Bronchodilator\n\n          -  Clinically stable in the last 4 weeks with no evidence of COPD exacerbation\n\n          -  Weight of 40 kg-120 kg\n\n          -  Willingness to use at least one form of acceptable birth control including\n             abstinence, condom with spermicide, or hormonal contraceptives\n\n          -  Willing to monitor blood glucose if known history of diabetes mellitus requiring\n             insulin or medical therapy\n\n        Exclusion Criteria:\n\n          -  Current Diagnosis of Asthma\n\n          -  Daytime use of Oxygen Therapy\n\n          -  Documented history of drug abuse within the last year\n\n          -  Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary\n             disease within 28 days before receiving the first dose of study drug.\n\n          -  Cirrhosis or elevated liver transaminases > 3X ULN\n\n          -  GFR < 50 estimated by Cockroft-Gault\n\n          -  Any illness of abnormal lab finding that, in the opinion of the investigator or the\n             subject's general practitioner, might confound the results of the study or pose an\n             additional risk in administering study drug to the subject.\n\n          -  Pregnant or Breastfeeding\n\n          -  Subjects taking any inhibitors or inducers of CYP3A4, including certain herbal\n             medications and grapefruit/grapefruit juice.\n\n          -  Uncontrolled Diabetes\n\n          -  Excluded medications and foods incude the drugs and foods provided in the appendix\n             document.\n\n          -  Clinically significant arrhythmias or conduction abnormalities that in the opinion of\n             the investigator affect patient safety have been added as exclusion criteria and\n             criteria for withdrawal."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135432", 
            "org_study_id": "F140319002", 
            "secondary_id": "TOPIC Trial"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ivacaftor (VX-770)", 
                "intervention_name": "Ivacaftor", 
                "intervention_type": "Drug", 
                "other_name": "Kalydeco"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Chronic Obstructive pulmonary disease, Ivacaftor", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "email": "hhathorne@peds.uab.edu", 
                "last_name": "Heather Y Hathorne, MAE", 
                "phone": "205-638-9568"
            }, 
            "contact_backup": {
                "email": "greeves@peds.uab.edu", 
                "last_name": "Ginger A Reeves, BS", 
                "phone": "638-5970"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35233"
                }, 
                "name": "University of Alabama at Birmingham"
            }, 
            "investigator": [
                {
                    "last_name": "Steven M Rowe, MD, MPH", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mark Dransfield, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)", 
        "other_outcome": {
            "measure": "Pharmacokinetics as described by AUC12 of subjects receiving ivacaftor", 
            "safety_issue": "No", 
            "time_frame": "at 6 months post baseline"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluate the efficacy of ivacaftor treatment in patients with COPD including measures of CFTR activity and clinical outcome as measured by change in lung function", 
                "measure": "Change in COPD as measured by lung function", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Evaluate the efficacy of ivacaftor treatment in patients with COPD including measures of CFTR activity and clinical outcome as measured by change sweat analysis.", 
                "measure": "Change in COPD as measured bysweat analysis", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "description": "Evaluate the efficacy of ivacaftor treatment in patients with COPD including measures of CFTR activity and clinical outcome as measured by change nasal potential difference measurements", 
                "measure": "change in COPD as measured by nasal potential difference measurements", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135432"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "mean number of adverse events per subject in each the Ivacaftor subjects and placebo subjects", 
            "measure": "Mean number of adverse events experienced by the Ivacaftor subjects and placebo subjects.", 
            "safety_issue": "Yes", 
            "time_frame": "baseline through 6 months (visit 5)"
        }, 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}